Executive Assistant

About Acrivon Therapeutics, Inc.

Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome.

These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development.

Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for EC. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on Onco Signature-predicted sensitivity in patients with EC.

The FDA has granted a Breakthrough Device designation for the ACR-368 Onco Signature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment.

In addition to ACR-368, Acrivon is also leveraging its proprietary Generative AI-driven Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity. The Phase 1/2 study of ACR-2316 is advancing in a randomized dose expansion study. Initial data has shown a highly differentiated, favorable safety profile primarily limited to only transient, mechanism-based hematological adverse events, predominantly only neutropenia.

Clinical activity has been observed across multiple tumor types, including SCLC, squamous NSCLC and lung adenocarcinoma, tumor types not shown sensitive to current single-agent WEE1 or PKMYT1 inhibitors. Durable clinical activity has been observed, with certain lung cancer subjects remaining on treatment more than one year.

In addition, the company is in early IND-enabling studies with several potential first-in-class development candidates targeting CDK
11.

Acrivon is seeking an experienced, eloquent, highly organized, and talented professional to join our team. This individual will provide executive administrative support, primarily to the CEO, as well as other C-level team members on an as needed basis. The individual must demonstrate a high degree of sophistication, tact, and discretion for dealing with information of a critical and confidential nature and be an advocate and credible representative for Acrivon and the CEO.

S/he will provide extensive coordination and communication with both external parties, including investment bankers, analysts, investors, collaborators, and other outside parties, as well as with Board members and the internal team across multiple geographies and time zones. In addition to strong interpersonal skills, to succeed in this role, the individual must have outstanding computer and troubleshooting skills, particularly with Microsoft Word, Excel, PowerPoint, and virtual meeting tools such as Zoom and Teams.

This individual must thrive in a fast-paced, fluid, and rapidly evolving corporate environment, and be adept at multi-tasking, yet detail-oriented with the ability to follow through and complete tasks in a timely and structured manner. The candidate will also from time to time be expected to make him/herself available for urgent matters if needed outside normal business hours, for instance in situations of travel disruptions, urgent financing or filing matters.

The individual must be a solution-oriented team player, whose actions exemplify integrity, dependability, adaptability, and self-confidence. This position is fully on site, five days per week, at Acrivon’s headquarters in Watertown, MA.

• Provide…